BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.370
+0.060 (4.58%)
At close: Aug 1, 2025, 4:00 PM
1.380
+0.010 (0.73%)
After-hours: Aug 1, 2025, 7:59 PM EDT

Company Description

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.

The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.

The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501.

BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc.
BioXcel Therapeutics logo
CountryUnited States
Founded2017
IPO DateMar 8, 2018
IndustryBiotechnology
SectorHealthcare
Employees37
CEOVimal Mehta

Contact Details

Address:
555 Long Wharf Drive, 12th Floor
New Haven, Connecticut 06511
United States
Phone475 238 6837
Websitebioxceltherapeutics.com

Stock Details

Ticker SymbolBTAI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001720893
CUSIP Number09075P105
ISIN NumberUS09075P2048
Employer ID82-1386754
SIC Code2834

Key Executives

NamePosition
Dr. Vimal D. Mehta Ph.D.Founder, Chief Executive Officer, President, and Director
Richard I. Steinhart MBASenior Vice President and Chief Financial Officer
Javier Rodriguez J.D.Senior Vice President, Chief Legal Officer and Corporate Secretary
Dr. Frank D. Yocca Ph.D.Executive Vice President and Chief Scientific Officer

Latest SEC Filings

DateTypeTitle
Aug 1, 20258-KCurrent Report
Jul 21, 20258-KCurrent Report
Jul 15, 20258-KCurrent Report
May 27, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13G/AFiling
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
Apr 4, 2025S-8Securities to be offered to employees in employee benefit plans
Apr 3, 20258-KCurrent Report